Mirion
MIR
16.45
+0.18
+1.11%
Mirion
US · MIR
#2362 by market cap
Listed 1970
16.45
+0.18
+1.11%
Live - 5344 symbols - heartbeat 433s ago
· 2026-10-08 07:27
Pre-market
16.29
-0.97%
After-hours
16.50
+0.30%
Overnight
16.04
-2.49%
- Market cap
- 4.00B
- P/E (TTM)i
- 182.78
- P/Bi
- 2.19
- EPSi
- 0.11
- Div yieldi
- 0.00%
- 52W posi
- 15%
Reader sentiment
Are you bullish or bearish on MIR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.74, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +7.50% YoY
Margins
- Gross margin
- 47.40%
- Operating margin
- 5.57%
- Net margin
- 3.11%
Key ratios & quality
- Enterprise valuei
- 4.79B
- Altman Z-Scorei
- 1.74
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 717.80M | 800.90M | 860.80M | 925.40M |
| Gross profit | -- | -- | -- | -- | 310.10M | 356.40M | 399.70M | 438.60M |
| Selling & admin expenses | -- | 341 | 2.45M | -- | 362.30M | 340.10M | 341.10M | 348.20M |
| Research & development | -- | -- | -- | -- | 30.30M | 31.70M | 35.00M | 38.90M |
| Operating profit | -- | -341 | -2.45M | -- | -82.50M | -15.40M | 23.60M | 51.50M |
| Pretax profit | -- | -341 | -45.52M | -- | -306.60M | -105.30M | -33.90M | 32.70M |
| Tax | -- | 0 | -265.90K | -- | -18.20M | -6.60M | 2.70M | 2.90M |
| Net profit | -- | -341 | -45.26M | -- | -288.40M | -98.70M | -36.60M | 29.80M |
| Basic EPS | -- | 0 | -1 | -- | -2 | 0 | 0 | 0 |
| Diluted EPS | -- | 0.00 | -0.79 | -- | -1.53 | -0.49 | -0.18 | 0.11 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 202.00M | 222.90M | 223.10M | 277.40M | 257.60M | 266.80M |
| Gross profit | 96.10M | 102.50M | 104.50M | 135.50M | 119.10M | 133.10M |
| Selling & admin expenses | 78.70M | 82.60M | 87.00M | 99.90M | 105.80M | 105.10M |
| Research & development | 8.70M | 10.00M | 10.10M | 10.10M | 9.60M | 10.10M |
| Operating profit | 8.70M | 9.90M | 7.40M | 25.50M | 3.70M | 17.90M |
| Pretax profit | 600.00K | 7.80M | 1.20M | 23.10M | -5.20M | 11.30M |
| Tax | 200.00K | -700.00K | -1.90M | 5.30M | -1.80M | 3.20M |
| Net profit | 400.00K | 8.50M | 3.10M | 17.80M | -3.40M | 8.10M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.00 | 0.03 | 0.01 | 0.06 | -0.01 | 0.03 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 5.00K | 5.00K | 982.42K | 453.40M | 480.60M | 538.60M | 594.70M | 893.70M |
| Cash & ST investments | 5.00K | 5.00K | 383.25K | 88.90M | 77.80M | 134.10M | 181.10M | 419.20M |
| Inventory | -- | -- | -- | 123.60M | 143.30M | 144.10M | 133.20M | 152.60M |
| Total assets | 5.00K | 5.00K | 751.32M | 3.12B | 2.74B | 2.72B | 2.64B | 3.59B |
| Total current liabilities | 295 | 636 | 73.02M | 221.00M | 244.30M | 265.70M | 263.50M | 316.10M |
| Short-term debt | -- | -- | -- | 13.20M | 13.80M | 8.00M | 7.60M | 9.30M |
| Long-term debt | -- | -- | -- | 806.80M | 801.50M | 684.70M | 685.20M | 1.20B |
| Total liabilities | 295.00 | 636.00 | 99,267,042.00 | 1,334,000,000.00 | 1,271,500,000.00 | 1,168,500,000.00 | 1,076,900,000.00 | 1,671,200,000.00 |
| Total equity | 4.71K | 4.36K | 652.05M | 1.78B | 1.47B | 1.55B | 1.56B | 1.92B |
| Retained earnings | -295 | -636 | -97.95M | -131.60M | -408.50M | -505.40M | -541.50M | -512.70M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 590.20M | 693.20M | 1.39B | 893.70M | 890.90M | 900.50M |
| Cash & ST investments | 191.70M | 268.70M | 939.70M | 419.20M | 404.90M | 425.30M |
| Inventory | 143.50M | 145.10M | 146.00M | 152.60M | 157.90M | 159.40M |
| Total assets | 2.63B | 2.74B | 3.50B | 3.59B | 3.54B | 3.52B |
| Total current liabilities | 265.00M | 272.40M | 287.00M | 316.10M | 279.20M | 281.60M |
| Short-term debt | 7.20M | 7.10M | 8.80M | 9.30M | 9.30M | 9.20M |
| Long-term debt | 685.90M | 832.40M | 1.20B | 1.20B | 1.20B | 1.20B |
| Total liabilities | 1,068,900,000.00 | 1,224,200,000.00 | 1,603,800,000.00 | 1,671,200,000.00 | 1,647,400,000.00 | 1,645,600,000.00 |
| Total equity | 1.56B | 1.51B | 1.89B | 1.92B | 1.89B | 1.88B |
| Retained earnings | -541.20M | -532.90M | -530.00M | -512.70M | -516.10M | -508.40M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -- | 0 | -945.35K | -- | 39.40M | 95.20M | 99.10M | 143.30M |
| Depreciation & amortization | -- | -- | -- | -- | 174.50M | 162.80M | 150.40M | 138.00M |
| Free cash flow | -- | 0 | -945.35K | -- | 5.20M | 58.10M | 50.30M | 106.90M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 750.00M | -- | 0 | 149.00M | -2.00M | 369.00M |
| Ending cash balance | -- | 5.00K | 750.45M | -- | 75.00M | 130.50M | 175.60M | 415.20M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 35.60M | 12.40M | 22.30M | 73.00M | 18.90M | 58.50M |
| Depreciation & amortization | 33.70M | 33.80M | 34.90M | 35.60M | 40.80M | 38.80M |
| Free cash flow | 27.10M | 3.60M | 13.00M | 63.20M | 9.40M | 48.10M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -20.50M | -34.30M | 425.00M | -1.20M | -20.10M | -25.80M |
| Ending cash balance | 186.20M | 263.00M | 933.60M | 415.20M | 400.80M | 421.60M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -7.52 | -0.29 | -- | -17.91 | -6.72 | -2.41 | 1.71 |
| ROA %i | -- | -6.82 | -0.28 | -- | -9.46 | -3.55 | -1.35 | 0.93 |
| ROIC %i | -- | -7.52 | -0.29 | -- | -9.89 | -1.95 | 0.20 | 2.11 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -36.88 | -5.42 | 2.79 | 8.09 |
| FCF / sales %i | -- | -- | -- | -- | 0.72 | 7.25 | 5.84 | 11.55 |
| Current ratioi | 16.95 | 7.86 | 0.01 | 2.05 | 1.97 | 2.03 | 2.26 | 2.83 |
| Quick ratioi | 16.95 | 7.86 | 0.01 | 1.40 | 1.24 | 1.37 | 1.65 | 2.24 |
| Debt / assetsi | -- | -- | -- | 27.60 | 31.02 | 26.51 | 27.31 | 34.38 |
| LT debt / equityi | -- | -- | -- | 50.05 | 59.78 | 48.02 | 47.31 | 65.60 |
| Interest coveragei | -- | -- | -- | -- | -6.32 | -0.70 | 0.41 | 1.77 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | 8.84 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | 173.94 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -0.68 | 0.67 | 1.58 | 1.71 | 1.50 | 1.49 |
| ROA %i | -0.38 | 0.37 | 0.86 | 0.93 | 0.81 | 0.78 |
| ROIC %i | 1.27 | 2.35 | 2.15 | 2.11 | 1.84 | 1.55 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 5.39 | 7.08 | 7.95 | 8.09 | 6.63 | 6.35 |
| FCF / sales %i | 9.68 | 9.45 | 10.28 | 11.55 | 9.09 | 13.05 |
| Current ratioi | 2.23 | 2.54 | 4.83 | 2.83 | 3.19 | 3.20 |
| Quick ratioi | 1.58 | 1.90 | 4.21 | 2.24 | 2.51 | 2.51 |
| Debt / assetsi | 27.40 | 31.60 | 35.27 | 34.38 | 34.90 | 35.02 |
| LT debt / equityi | 47.37 | 58.67 | 66.47 | 65.60 | 66.62 | 67.04 |
| Interest coveragei | 0.85 | 1.22 | 1.55 | 1.77 | 1.71 | 1.88 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Nuclear & Safety is the largest reported line at 69.79% of revenue, across 2 reported segments.
- Medical follows at 30.21%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Nuclear & Safety69.79%
Medical30.21%
Quote time 2026-10-08 07:27:18 · For reference only, not investment advice and not tailored to your situation.